San Diego, CA – Cortechs.ai, a leader in AI-driven neuroimaging software, today announces the acquisition of intellectual property from ZepMed, LLC, including its patented CT imaging technologies and flagship product, NeuroQuant CT™. This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions for clinicians worldwide.
“With this acquisition, we’re not just expanding our portfolio, we’re building on ZepMed’s foundation to elevate development and deliver even more powerful tools to our users,” said Kyle Frye, CEO of Cortechs.ai. “This is an exciting growth milestone as we continue to enhance the solutions trusted by healthcare professionals around the globe.”
ZepMed, renowned for its pioneering work in CT imaging, developed NeuroQuant CT™, a Class II FDA-cleared software that automates segmentation, alignment, and reformatting of head CT scans. The technology enhances diagnostic accuracy and streamlines radiology workflows, empowering clinicians to detect subtle changes in brain anatomy with greater confidence and speed.
“We at Zepmed are proud of what we built with NeuroAlign®, and we are excited to see it reach its full potential in the hands of Cortechs.ai,” said Douglas Bates, MD, co-founder of ZepMed. “Cortechs’ support and development team will enhance user experience and add features, ensuring that the technology benefits more clinicians and patients worldwide.”
“This ownership strengthens our commitment to delivering AI-powered diagnostic solutions that span both neuroimaging and radiology,” said Daniel Livschutz, Chairman of the Board for Cortechs.ai and Founding Partner of VILAS Ventures. “As investors, we’re proud to support Cortechs.ai’s record growth, IP ownership and strategic expansion as market leaders. With the integration of ZepMed’s innovations, we’re not just adding capabilities, we’re architecting a continuum of care that spans surveillance, diagnosis, and risk. This positions Cortechs to complete the entire precision medicine value chain, moving beyond silos toward a multimodal ecosystem that better serves patients, clinicians, and payers alike. We’re excited to continue building the Cortechs.ai platform and look forward to the impact it will drive worldwide.”
By bringing ZepMed’s technology under its ownership, Cortechs.ai accelerates innovation and broadens its neuroimaging portfolio, reinforcing its leadership in AI-powered radiology and its mission to improve patient outcomes through precision diagnostics.
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company has FDA-cleared products for use in helping the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.
For more information, please contact:
___________
info@cortechs.ai
+1 858 459 9700
About ZepMed
ZepMed is an innovator in medical imaging software, specializing in advanced CT solutions that enhance radiology interpretation speed and accuracy. Its flagship product, NeuroQuant CT™, is FDA-cleared and patented, providing radiologists with tools to achieve faster and more reliable diagnoses. ZepMed’s technology has been recognized for transforming radiology workflows and improving diagnostic confidence.
